知镜 Cognispect · 医学文献与研究工作台

Clinical, radiological, and pathological features of pulmonary hypertension associated with combined pulmonary fibrosis and emphysema.

He M, Zhao Q, Xie H, Zhang R, Liu J, Xie W, Yu Y, Wu Y, Zhang J, Wu C, Gong S, Wang L.
Respiratory research · 2026-07-27 · PMID 42907855

文献摘要

Background Combined pulmonary fibrosis and emphysema-associated pulmonary hypertension (CPFE-PH) has emerged as a distinct third category of PH, yet its detailed clinical-hemodynamic profile, pathological features, and comparative outcomes remain poorly defined. This study aims to characterize the phenotype of CPFE-PH and compare it with chronic obstructive pulmonary disease-related PH (COPD-PH) and idiopathic interstitial pneumonia-related PH (IIP-PH). Methods In this multicenter cohort study, we analyzed 113 patients with CPFE-PH, 277 with COPD-PH, and 78 with IIP-PH, all diagnosed by right heart catheterization. Clinical, physiological, imaging, pathological, treatment response, and survival data were statistically compared across groups. Results CPFE-PH patients were older, predominantly male smokers, and exhibited preserved ventilatory function but severely reduced diffusing capacity (DL CO 31.6% predicted, IQR 24.8-37.8). They had the most severe hemodynamic compromise (mean pulmonary arterial pressure 41 mmHg, pulmonary vascular resistance 7.4 Wood units), a high prevalence of mediastinal lymphadenopathy (81.4%), and universal capillary hemangiomatosis-like remodeling, a pathological feature absent in COPD-PH and rarely observed in IIP-PH. Pulmonary arterial hypertension-targeted therapy failed to improve functional or biomarker outcomes, and transplant-free survival was shortest in CPFE-PH (median 32 months) compared with COPD-PH and IIP-PH (P Conclusions CPFE-PH appears to represent a severe phenotype within Group 3 PH, in which prominent capillary remodeling, including hemangiomatosis-like changes, may contribute to its clinical, radiological, and functional manifestations, distinguish it from other Group 3 PH types. Clinical trial Chinese Clinical Study.org, No: ChiCTR2000032212, Registration Date: 2020-04-23; URL: http://www.chictr.org.cn/ .

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。